ClinicalTrials.gg
TerminatedNCT04059406Updated Feb 18, 2025Results posted

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

A Phase 2 interventional study of sapablursen in Beta Thalassemia Intermedia, sponsored by Ionis Pharmaceuticals, Inc.. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Favorable safety and tolerability were seen, but efficacy results in the mid-stage study did not meet Ionis' minimum target product profile to justify further development.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in beta-Thalassemia with a site in Thailand — 2 open to participants now, 6 under way, 3 of them phase 3. beta-Thalassemia · Thailand.

Enrollment
12th of 22
29 · median 30
Started
2020
with 2 others
Phase 2
13 of 24
1 open now
Registered
19th of 24
by date

Among the 24 studies in beta-Thalassemia with a site in Thailand, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 in phase 2, and was the 19th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

2 of the 24 studies in beta-Thalassemia with a site in Thailand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in beta-Thalassemia with a site in Thailand, or all of them as a file.
02

Study summary

The purpose was to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of sapablursen administered subcutaneously to participants with non-transfusion dependent β-Thalassemia Intermedia.

Read the detailed description

This was a multi-center, randomized, open-label study in up to 29 participants. The duration of participation for each subject in the study was approximately 29 months and included an approximately 2-month screening period, a 24-month treatment period, and a 3-month post-treatment period.

03

Conditions studied

  • Beta Thalassemia Intermedia

Keywords

  • Thalassaemia
  • Beta Thalassemia
  • IONIS TMPRSS6-LRx
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to comply with study procedures
  • Clinical diagnosis of Beta-Thalassemia Intermedia with genotypic confirmation
  • Non-transfusion dependent, as defined by: no more than 6 transfusions in the past 12-month period, and no transfusions in the 8-week period prior to Day 1
  • Mean within the range of 6.0-10.0 g/dL, inclusive at Screening
  • LIC within the range of 3.0-20.0 mg Fe/g dry weight, inclusive
  • If using chelators, must be on a stable dose for at least 3 months with liver iron concentration (LIC) > 5.0 mg iron (Fe) per gram of dry weight of liver (Fe/g) dry weight and serum ferritin > 300 nanograms per milliliter (ng/mL)
  • Females must be non-pregnant and non-lactating, and either surgically sterile or
  • Males must be surgically sterile, abstinent or using an acceptable method

Exclusion criteria

Exclusion Criteria:

  • abnormalities in lab values, medical history, or physical examination
  • α-globin gene triplication
  • Symptomatic splenomegaly
  • count \< lower limit of normal (LLN) or > 1,000 x 10\^9/L
  • Significant concurrent/recent coagulopathy, history of non-traumatic significant bleeding; history of immune thrombocytopenic purpura (ITP); current use of SC anti-coagulants; history of thrombotic events, including stroke or DVT
  • Clinically significant renal, liver or cardiac dysfunction
  • Uncontrolled hypertension (> 140 mm Hg systolic or > 90 mm Hg diastolic)
  • Fasting blood glucose > 2.0 × (ULN)
  • Inability to have a magnetic resonance imaging (MRI) scan
  • Known history or positive test for (HIV), (HCV), or (HBV)
  • Active infection requiring systemic antiviral or antimicrobial therapy
  • Regular excessive use of alcohol
  • Recent start of hydroxyurea (6 months prior to Day 1)
  • Treatment with or recent exposure to another drug, biological agent, antisense oligonucleotide (ASO), small interfering ribonucleic acid (siRNA), or device within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer; or treatment with or exposure to:

    • sotatercept (ACE-011), luspatercept (ACE-536), or ruxolitinib within 4 months of Screening
    • hematopoietic stimulating agents or any hypoxia-inducible factor prolyl hydroxylase inhibitors within 8 weeks of Day 1
    • prior bone marrow transplant, stem cell transplant, or gene therapy
  • Surgery associated with significant blood loss within 4 months of Screening, splenectomy within 12 months of Screening, or splenectomy scheduled during treatment
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Cohort A: Sapablursen

    Subjects initially received 30 mg/0.3 mL of sapablursen by (subcutaneous) SC injection once every four weeks up to Week 105. After the protocol Amendment 2 the dose was increased to a maximum of 160 mg once every 4 weeks.

    Drug: sapablursen

  • Experimental
    Cohort B: Sapablursen

    Subjects initially received 50 mg/0.5 mL of sapablursen by SC injection once every four weeks up to Week 105. After the protocol Amendment 2 the dose was increased to a maximum of 160 mg once every 4 weeks

    Drug: sapablursen

  • Experimental
    Cohort C: Sapablursen

    Subjects initially received 80 mg/0.8 mL of sapablursen by SC injection once every four weeks up to Week 105. After the protocol Amendment 2 the dose was increased to a maximum of 160 mg once every 4 weeks.

    Drug: sapablursen

Interventions

  • sapablursen administered subcutaneously

    Also known as: ISIS 702843, IONIS TMPRSS6-LRx

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27

    Blood hemoglobin

    Time frame: Baseline and Week 27

Secondary outcomes

  1. Percentage of Participants With a ≥1.5 g/dL Increase From Baseline in Hb at Week 53

    Blood hemoglobin

    Time frame: Week 53

  2. Percentage of Participants With a ≥1.0 Milligrams of Iron Per Grams of Dry Weight of Liver (mg Fe/g) Decrease From Baseline in Liver Iron Concentration (LIC) at Week 53

    Liver iron content

    Time frame: Week 53

07

Results

Posted Feb 18, 2025

Participant flow

Participants were enrolled in the study at 15 investigative sites in Australia, Greece, Lebanon, Thailand, and Turkey from 24 September 2020 to 28 March 2023.

Participant flow — Overall Study
MilestoneCohort A: SapablursenCohort B: SapablursenCohort C: Sapablursen
Started6617
Completed112
Not completed5515
Withdrew: Early treatment termination5515

Outcome measures

PrimaryPercentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27

Blood hemoglobin

Time frame:
Baseline and Week 27
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27
percentage of participantsCohort A: SapablursenCohort B: SapablursenCohort C: Sapablursen
Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 270 (0.0 to 45.9)0 (0.0 to 45.9)6.7 (0.2 to 31.9)
SecondaryPercentage of Participants With a ≥1.5 g/dL Increase From Baseline in Hb at Week 53

Blood hemoglobin

Time frame:
Week 53
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥1.5 g/dL Increase From Baseline in Hb at Week 53
percentage of participantsCohort A: SapablursenCohort B: SapablursenCohort C: Sapablursen
Percentage of Participants With a ≥1.5 g/dL Increase From Baseline in Hb at Week 530 (0.0 to 45.9)0 (0.0 to 45.9)0 (0.0 to 23.2)
SecondaryPercentage of Participants With a ≥1.0 Milligrams of Iron Per Grams of Dry Weight of Liver (mg Fe/g) Decrease From Baseline in Liver Iron Concentration (LIC) at Week 53

Liver iron content

Time frame:
Week 53
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥1.0 Milligrams of Iron Per Grams of Dry Weight of Liver (mg Fe/g) Decrease From Baseline in Liver Iron Concentration (LIC) at Week 53
percentage of participantsCohort A: SapablursenCohort B: SapablursenCohort C: Sapablursen
Percentage of Participants With a ≥1.0 Milligrams of Iron Per Grams of Dry Weight of Liver (mg Fe/g) Decrease From Baseline in Liver Iron Concentration (LIC) at Week 5333.3 (4.3 to 77.7)50.0 (11.8 to 88.2)28.6 (8.4 to 58.1)

Adverse events

Collected over From signing of informed consent to early termination (up to 733 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Sapablursen0/6 (0%)0/6 (0%)6/6 (100%)
Cohort B: Sapablursen0/6 (0%)2/6 (33.3%)6/6 (100%)
Cohort C: Sapablursen0/17 (0%)1/17 (5.9%)14/17 (82.4%)
Most frequent serious events
Most frequent serious events
EventCohort A: SapablursenCohort B: SapablursenCohort C: Sapablursen
Forearm FractureInjury, poisoning and procedural complications0/61/60/17
COVID-19Infections and infestations0/61/60/17
PneumoniaInfections and infestations0/61/60/17
Portal vein thrombosisHepatobiliary disorders0/60/61/17
Most frequent other events
Showing 10 of 88
Most frequent other events
EventCohort A: SapablursenCohort B: SapablursenCohort C: Sapablursen
FatigueGeneral disorders4/61/61/17
COVID-19Infections and infestations3/60/611/17
Injection Site RashGeneral disorders0/62/60/17
Vaccination Site PainGeneral disorders2/61/61/17
HeadacheNervous system disorders0/62/62/17
Abdominal Pain UpperGastrointestinal disorders1/62/60/17
Abdominal DistensionGastrointestinal disorders0/62/60/17
MyalgiaMusculoskeletal and connective tissue disorders2/61/63/17
Back PainMusculoskeletal and connective tissue disorders1/62/62/17
InfluenzaInfections and infestations2/62/61/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A: SapablursenCohort B: SapablursenCohort C: SapablursenTotal
Mean35.0 ± 12.1231.7 ± 10.4432.0 ± 10.8832.6 ± 10.72
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: SapablursenCohort B: SapablursenCohort C: SapablursenTotal
Female441018
Male22711
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: SapablursenCohort B: SapablursenCohort C: SapablursenTotal
Race — White35917
Race — Asian31812
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: SapablursenCohort B: SapablursenCohort C: SapablursenTotal
Ethnicity — Not Hispanic or Latino661729
08

Study locations

19 sites
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Aghia Sophia General Children's Hospital
    Athens, Attica 115 27, Greece
  • University General Hospital of Patras
    Patra, Peloponnese 26 504, Greece
  • Koutlimbaneio & Triantafylleio General Hospital of Larissa
    Larissa, Thessaly 412 21, Greece
  • Chronic Care Center
    Hazmiyeh, Lebanon
  • Siriraj Hospital
    Bangkok, 10700, Thailand
  • Maharaj Nakorn Chiang Mai Hospital
    Chiang Mai, 50200, Thailand
  • Srinagarind Hospital
    Khon Kaen, 40002, Thailand
  • Thammasat University Hospital
    Pathum Thani, 12120, Thailand
  • King Chulalongkorn Memorial Hospital
    Pathum Wan, 10330, Thailand
  • Naresuan University Hospital
    Phitsanulok, 65000, Thailand
  • Songklanagarind Hospital
    Songkhla, 90110, Thailand
  • Cukurova Üniversitesi Tıp Fakültesi
    Adana, 1330, Turkey
  • Hacettepe Üniversitesi Tıp Fakültesi
    Ankara, 6100, Turkey
  • Akdeniz University Faculty of Medicine
    Antalya, 07070, Turkey
  • Ege Universitesi Tip Fakultesi
    İzmir, 35100, Turkey
  • İstanbul Üniversitesi - Istanbul Tıp Fakültesi
    Topkapı, 34093, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Mar 2023, 30 months.

Results were first posted in Feb 2025, 1 year 10 months after primary completion. A results delay was requested in Feb 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2019
First posted
Aug 16, 2019
StartActual
Sep 24, 2020
Primary completionActual
Mar 28, 2023
CompletionActual
Mar 28, 2023
Results delay requested
Feb 26, 2024
Results first posted
Feb 18, 2025
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04059406
Responsible party
Sponsor
First posted
Aug 16, 2019
Start date
Sep 24, 2020
Primary completion
Mar 28, 2023
Completion
Mar 28, 2023
Results posted
Feb 18, 2025
Last update
Feb 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sapablursen

Start the discussion